ALGS today
$2.10+$0.12 (+6.06%)close Nov 13, 2026Trend
DailyDowntrend (confirmed)
4 hourLeaning Bullish
1 hourLeaning Bullish
15 minStrong Bearish
5 minStrong Bullish
Daily trend turns up above $18.75
Key levels
Resistance$4.55
Resistance$3.98
Latest news & SEC filings
EarningsAligos Therapeutics Posts Third-Quarter 2026 Results
ProductAligos Therapeutics reports positive data at AASLD Liver Meeting 2026
EarningsAligos Therapeutics posts Q3 loss of $2.09 per share, revenue $2.830M
SEC FilingAligos Therapeutics, Inc. filed a report on a major company event (Form 8-K)
All ALGS news →About Aligos Therapeutics
Aligos Therapeutics is a biopharmaceutical company in the clinical phase of development, working on new medicines for liver conditions and viral illnesses. Its programs target chronic hepatitis B, fatty liver disease linked to metabolic problems, weight gain, and coronaviruses. The company is based in the United States and works with partners in Asia.
Based on the company's 10-K filed Mar 5, 2026.
Nasdaq · Healthcare
Aligos Therapeutics, Inc. (ALGS)
What Is the Price Target for ALGS?
SEPT Low Target
$20.00
SEPT Mid Target
$32.50
SEPT High Target
$45.00
Analyst Consensus
$32.50
Is ALGS a Buy or Sell Right Now?
Thesis
- •Revenue growing -39.5% YoY with ACCELERATING trend — accelerating momentum.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ALGS.
Start Free Trial →Is ALGS Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$25.04
22
Moat Score
NONE
3/9
Piotroski Score
-11.8
Altman Z-Score
What Is Smart Money Doing with ALGS?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →ALGS Growth Story
Revenue YoY
-39.5%
3yr Revenue CAGR
N/A%
EPS Growth YoY
88.3%
FCF Growth YoY
N/A%
Revenue Trend
ACCELERATING
Dark Pool Trades for ALGS
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for ALGS, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 15:32:13 | $1.99 | 1,000 | $$2K | BUY |
| 15:22:07 | $1.99 | 1,000 | $$2K | BUY |
| 21:00:00 | $1.98 | 1,306 | $$3K | MIDPOINT |
| 20:58:28 | $1.98 | 1,458 | $$3K | BUY |
| 20:58:15 | $1.98 | 2,150 | $$4K | BUY |
5 dark pool trades shown · $$14K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Aligos Therapeutics, Inc. (ALGS) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (5 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →ALGS — frequently asked questions
What is ALGS stock price today?
Aligos Therapeutics, Inc. (ALGS) is at $2.10, up 6.06% (+$0.12) at the Nov 13, 2026 close.
Why is ALGS stock moving today?
Latest ALGS news — Nov 6, 2026: Aligos Therapeutics Posts Third-Quarter 2026 Results · Nov 6, 2026: Aligos Therapeutics reports positive data at AASLD Liver Meeting 2026
Why did ALGS stock move on Nov 6, 2026?
Aligos Therapeutics shares fell 8.33% to close at $4.07 after the company reported third-quarter 2026 results, posting a loss of $2.09 per share on revenue of $2.830 million. While the loss per share came in smaller than analysts expected, the top line fell short of consensus, weighing on the stock.
What is the ALGS price target?
The average analyst price target for ALGS is $32.50, ranging from $20 to $45, based on 2 analysts. Latest: Lake Street initiates on May 28, 2026.
What do analysts rate ALGS?
Analyst ratings for ALGS: 0 Buy, 3 Hold, 0 Sell — consensus Hold.
Did ALGS beat earnings?
ALGS last reported on Nov 6, 2026: EPS -$2.09 vs -$2.28 expected — a beat of 8.3%.
Does ALGS pay a dividend?
ALGS does not currently pay a dividend.
What are ALGS support and resistance levels?
Resistance: $3.98, $4.55, $5.38.
What are insiders doing with ALGS?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on ALGS?
Nov 6, 2026: Aligos Therapeutics Posts Third-Quarter 2026 Results · Nov 6, 2026: Aligos Therapeutics reports positive data at AASLD Liver Meeting 2026 · Nov 6, 2026: Aligos Therapeutics posts Q3 loss of $2.09 per share, revenue $2.830M